Compare OZ & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | PROF |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.7M | 248.8M |
| IPO Year | 2020 | 2017 |
| Metric | OZ | PROF |
|---|---|---|
| Price | $43.86 | $5.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 11.8K | ★ 127.0K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ N/A |
| Revenue | $9,187,000.00 | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 243.44 | 50.73 |
| 52 Week Low | $42.59 | $4.86 |
| 52 Week High | $69.00 | $8.95 |
| Indicator | OZ | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 27.84 | 36.91 |
| Support Level | N/A | $4.97 |
| Resistance Level | $45.99 | $6.06 |
| Average True Range (ATR) | 0.87 | 0.36 |
| MACD | -0.43 | -0.03 |
| Stochastic Oscillator | 30.67 | 20.00 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.